The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant pembrolizumab (pembro) and accelerated methotrexate, vinblastine, doxorubicin, cisplatin (aMVAC) in non-urothelial (non-UC) histologic subtype muscle invasive bladder cancer (MIBC): A phase 2 trial.
 
Ruben Raychaudhuri
No Relationships to Disclose
 
Ali Khaki
Honoraria - HMP
Consulting or Advisory Role - Gilead Sciences (Inst)
Research Funding - 23andMe (Inst); Acrivon Therapeutics (Inst); Janssen Oncology (Inst); Pfizer (Inst)
(OPTIONAL) Uncompensated Relationships - Janssen; Pfizer/Astellas
 
Mary Redman
No Relationships to Disclose
 
Kelsey Baker
No Relationships to Disclose
 
Aaron Lin
No Relationships to Disclose
 
Brianna Woo
No Relationships to Disclose
 
Andrii Hannochka
No Relationships to Disclose
 
Nathan Conrad
No Relationships to Disclose
 
Funda Vakar-Lopez
No Relationships to Disclose
 
Todd Yezefski
Honoraria - Pfizer/Myovant
Consulting or Advisory Role - Dendreon
 
Michael Schweizer
Consulting or Advisory Role - AstraZeneca; FibroGen; Janssen; Pfizer; Sanofi
Research Funding - Ambrx (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Epigenetix (Inst); Immunomedics (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SignalOne Bio (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Zenith Epigenetics (Inst)
 
Robert Montgomery
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Beigene (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst)
 
Evan Yu
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Bristol Myers Squibb; Janssen; Loxo/Lilly; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Oncternal Therapeutics (Inst); Seagen (Inst); Tyra Biosciences (Inst)
 
Atreya Dash
Research Funding - Intuitive Surgical (Inst)
Travel, Accommodations, Expenses - Intuitive Surgical
 
Sarah Psutka
Leadership - Janssen
Honoraria - AstraZeneca
Consulting or Advisory Role - CG Oncology; ImmunityBio; Janssen; Merck
Research Funding - Janssen; Steba Biotech
Travel, Accommodations, Expenses - medtronic
 
Daniel Lin
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Lantheus Medical Imaging
Research Funding - GenomeDx (Inst); Magforce (Inst); MDxHealth (Inst)
 
George Schade
Consulting or Advisory Role - EDAP TMS; ImmunityBio
Patents, Royalties, Other Intellectual Property - Petal Surgical
 
John Gore
Consulting or Advisory Role - Astellas Pharma
 
Jonathan Wright
Consulting or Advisory Role - ImmunityBio; pacific edge
Research Funding - Bristol-Myers Squibb/Sanofi; Janssen Oncology; Merck; pacific edge; Seagen
Patents, Royalties, Other Intellectual Property - Royalties from UpToDate for chapter I wrote.
 
Petros Grivas
Consulting or Advisory Role - Abbvie; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; CG Oncology; Daiichi Sankyo; EMD Serono; Fresenius Kabi; Gilead Sciences; ImmunityBio; Janssen; Merck; Pfizer; Replimune; Roche; Strata Oncology
Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Mirati Therapeutics (Inst); QED Therapeutics (Inst)